PAM
ALNY icon

Pinpoint Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Pinpoint Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-13,100
Closed -$2.22M – 29
2021
Q2 		$2.22M Buy
13,100
+4,100
+46% +$600K 0.54% 21
2021
Q1 		$1.27M Buy
+9,000
New +$1.35M 0.32% 25

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Pinpoint Asset Management's ALNY Position: Q3 2021 in Review

Pinpoint Asset Management sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2021, closing a stake of 13,100 shares — an estimated $2.22M sold.

Pinpoint Asset Management first reported a position in ALNY in Q1 2021 and held it in 2 quarters. The position peaked at $2.22M in Q2 2021. 405 funds tracked by Wall St. Rank hold ALNY as of Q3 2021.

  • Pinpoint Asset Management reported no remaining Alnylam Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Pinpoint Asset Management sold 13,100 Alnylam Pharmaceuticals shares in Q3 2021, an estimated $2.22M.
  • Pinpoint Asset Management first reported a position in Alnylam Pharmaceuticals in Q1 2021 and held it in 2 quarters.
  • Pinpoint Asset Management's Alnylam Pharmaceuticals position peaked at $2.22M in Q2 2021.
  • 405 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2021.

Based on Pinpoint Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.